Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori: Effect of sofalcone

Masayuki Suzuki, Tetsuo Kitahora, Shouichi Nagahashi, Hidekazu Suzuki, Mikiji Mori, Toshifumi Hibi, Hiromasa Ishii

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Eradication therapy for Helicobacter pylori (H. pylori) has been established. However, the physiological factors influencing the success of treatment remain unclear. The aim of this study was to analyze these factors and to evaluate the efficacy of sofalcone on H. pylori eradication therapy. Forty-four H. pylori-infected and peptic ulcer patients were enrolled in this study. Twenty-seven patients were treated with lansoprazole (LPZ, 30 mg o.d. for 1-8 weeks) and amoxicillin (AMPC, 500 mg q.i.d, 1-2 weeks), followed by 8 weeks of treatment with famotidine (FAM, 20 mg o.d.). Moreover, sofalcone (SOF, 100 mg t.i.d) was administered to 17 patients throughout the therapeutic period. Endoscopic and serologic evaluations and the urea breath test (UBT) were performed before therapy. At the endoscopic examination, mucosal samples were biopsied and then tissue myeloperoxidase (MPO) content, an index of neutrophil infiltration was measured. Cure of H. pylori infection was determined 8 weeks after the cessation of LPZ. This eradication regimen afforded an overall cure rate of 63.0% (17/27) without SOF and 76.5% (13/17) with SOF. In the control group, treatment success was inversely associated with pre-UBT value (gastric urease activity), whereas this association was not observed in the SOF group. Furthermore, in the patients exhibiting a high pre-UBT value (>40%), a twofold higher eradication rate was obtained by the administration of SOF. In patients who were successfully eradicated, mucosal MPO level was slightly higher than those of unsuccessful cases, whereas there was no significant association with serum pepsinogen (PG I, PG II) concentration and its ratio (PG I/PG II). These results suggest that a low UBT value is a factor predicting treatment success. SOF administration may improve the eradication rate, especially in the high-UBT subgroup.

Original languageEnglish
JournalJournal of Clinical Gastroenterology
Volume27
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 1998

Fingerprint

Urease
Helicobacter pylori
Stomach
Breath Tests
Urea
Therapeutics
Peroxidase
Famotidine
Lansoprazole
Pepsinogen A
Neutrophil Infiltration
sofalcone
Amoxicillin
Helicobacter Infections
Peptic Ulcer
Statistical Factor Analysis
Control Groups
Serum

Keywords

  • Eradication
  • Helicobacter pylori
  • Sofalcone
  • Urea breath test

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori : Effect of sofalcone. / Suzuki, Masayuki; Kitahora, Tetsuo; Nagahashi, Shouichi; Suzuki, Hidekazu; Mori, Mikiji; Hibi, Toshifumi; Ishii, Hiromasa.

In: Journal of Clinical Gastroenterology, Vol. 27, No. SUPPL. 1, 1998.

Research output: Contribution to journalArticle

Suzuki, Masayuki ; Kitahora, Tetsuo ; Nagahashi, Shouichi ; Suzuki, Hidekazu ; Mori, Mikiji ; Hibi, Toshifumi ; Ishii, Hiromasa. / Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori : Effect of sofalcone. In: Journal of Clinical Gastroenterology. 1998 ; Vol. 27, No. SUPPL. 1.
@article{3e8d939ebc8b41b19faf9d2528ff538c,
title = "Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori: Effect of sofalcone",
abstract = "Eradication therapy for Helicobacter pylori (H. pylori) has been established. However, the physiological factors influencing the success of treatment remain unclear. The aim of this study was to analyze these factors and to evaluate the efficacy of sofalcone on H. pylori eradication therapy. Forty-four H. pylori-infected and peptic ulcer patients were enrolled in this study. Twenty-seven patients were treated with lansoprazole (LPZ, 30 mg o.d. for 1-8 weeks) and amoxicillin (AMPC, 500 mg q.i.d, 1-2 weeks), followed by 8 weeks of treatment with famotidine (FAM, 20 mg o.d.). Moreover, sofalcone (SOF, 100 mg t.i.d) was administered to 17 patients throughout the therapeutic period. Endoscopic and serologic evaluations and the urea breath test (UBT) were performed before therapy. At the endoscopic examination, mucosal samples were biopsied and then tissue myeloperoxidase (MPO) content, an index of neutrophil infiltration was measured. Cure of H. pylori infection was determined 8 weeks after the cessation of LPZ. This eradication regimen afforded an overall cure rate of 63.0{\%} (17/27) without SOF and 76.5{\%} (13/17) with SOF. In the control group, treatment success was inversely associated with pre-UBT value (gastric urease activity), whereas this association was not observed in the SOF group. Furthermore, in the patients exhibiting a high pre-UBT value (>40{\%}), a twofold higher eradication rate was obtained by the administration of SOF. In patients who were successfully eradicated, mucosal MPO level was slightly higher than those of unsuccessful cases, whereas there was no significant association with serum pepsinogen (PG I, PG II) concentration and its ratio (PG I/PG II). These results suggest that a low UBT value is a factor predicting treatment success. SOF administration may improve the eradication rate, especially in the high-UBT subgroup.",
keywords = "Eradication, Helicobacter pylori, Sofalcone, Urea breath test",
author = "Masayuki Suzuki and Tetsuo Kitahora and Shouichi Nagahashi and Hidekazu Suzuki and Mikiji Mori and Toshifumi Hibi and Hiromasa Ishii",
year = "1998",
doi = "10.1097/00004836-199800001-00030",
language = "English",
volume = "27",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori

T2 - Effect of sofalcone

AU - Suzuki, Masayuki

AU - Kitahora, Tetsuo

AU - Nagahashi, Shouichi

AU - Suzuki, Hidekazu

AU - Mori, Mikiji

AU - Hibi, Toshifumi

AU - Ishii, Hiromasa

PY - 1998

Y1 - 1998

N2 - Eradication therapy for Helicobacter pylori (H. pylori) has been established. However, the physiological factors influencing the success of treatment remain unclear. The aim of this study was to analyze these factors and to evaluate the efficacy of sofalcone on H. pylori eradication therapy. Forty-four H. pylori-infected and peptic ulcer patients were enrolled in this study. Twenty-seven patients were treated with lansoprazole (LPZ, 30 mg o.d. for 1-8 weeks) and amoxicillin (AMPC, 500 mg q.i.d, 1-2 weeks), followed by 8 weeks of treatment with famotidine (FAM, 20 mg o.d.). Moreover, sofalcone (SOF, 100 mg t.i.d) was administered to 17 patients throughout the therapeutic period. Endoscopic and serologic evaluations and the urea breath test (UBT) were performed before therapy. At the endoscopic examination, mucosal samples were biopsied and then tissue myeloperoxidase (MPO) content, an index of neutrophil infiltration was measured. Cure of H. pylori infection was determined 8 weeks after the cessation of LPZ. This eradication regimen afforded an overall cure rate of 63.0% (17/27) without SOF and 76.5% (13/17) with SOF. In the control group, treatment success was inversely associated with pre-UBT value (gastric urease activity), whereas this association was not observed in the SOF group. Furthermore, in the patients exhibiting a high pre-UBT value (>40%), a twofold higher eradication rate was obtained by the administration of SOF. In patients who were successfully eradicated, mucosal MPO level was slightly higher than those of unsuccessful cases, whereas there was no significant association with serum pepsinogen (PG I, PG II) concentration and its ratio (PG I/PG II). These results suggest that a low UBT value is a factor predicting treatment success. SOF administration may improve the eradication rate, especially in the high-UBT subgroup.

AB - Eradication therapy for Helicobacter pylori (H. pylori) has been established. However, the physiological factors influencing the success of treatment remain unclear. The aim of this study was to analyze these factors and to evaluate the efficacy of sofalcone on H. pylori eradication therapy. Forty-four H. pylori-infected and peptic ulcer patients were enrolled in this study. Twenty-seven patients were treated with lansoprazole (LPZ, 30 mg o.d. for 1-8 weeks) and amoxicillin (AMPC, 500 mg q.i.d, 1-2 weeks), followed by 8 weeks of treatment with famotidine (FAM, 20 mg o.d.). Moreover, sofalcone (SOF, 100 mg t.i.d) was administered to 17 patients throughout the therapeutic period. Endoscopic and serologic evaluations and the urea breath test (UBT) were performed before therapy. At the endoscopic examination, mucosal samples were biopsied and then tissue myeloperoxidase (MPO) content, an index of neutrophil infiltration was measured. Cure of H. pylori infection was determined 8 weeks after the cessation of LPZ. This eradication regimen afforded an overall cure rate of 63.0% (17/27) without SOF and 76.5% (13/17) with SOF. In the control group, treatment success was inversely associated with pre-UBT value (gastric urease activity), whereas this association was not observed in the SOF group. Furthermore, in the patients exhibiting a high pre-UBT value (>40%), a twofold higher eradication rate was obtained by the administration of SOF. In patients who were successfully eradicated, mucosal MPO level was slightly higher than those of unsuccessful cases, whereas there was no significant association with serum pepsinogen (PG I, PG II) concentration and its ratio (PG I/PG II). These results suggest that a low UBT value is a factor predicting treatment success. SOF administration may improve the eradication rate, especially in the high-UBT subgroup.

KW - Eradication

KW - Helicobacter pylori

KW - Sofalcone

KW - Urea breath test

UR - http://www.scopus.com/inward/record.url?scp=0032433919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032433919&partnerID=8YFLogxK

U2 - 10.1097/00004836-199800001-00030

DO - 10.1097/00004836-199800001-00030

M3 - Article

C2 - 9872519

AN - SCOPUS:0032433919

VL - 27

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - SUPPL. 1

ER -